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1. Introduction 
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that is highly expressed in 
cells of haematopoietic lineage, where it has an important role in the intra-cellular signalling 
cascades for various immunoreceptors, such as the B cell receptor and the Fc receptor. As 
such, it is a potential target in allergic and autoimmune diseases. Emerging evidence also 
suggests that Syk may have additional roles beyond its well defined functions in classical 
immunoreceptor signalling, which may have implications, potentially useful or harmful, for 
therapies directed at this protein. Given these diverse functions in numerous cell types, it is 
unsurprising that Syk has been the subject of hundreds of original research articles, as well 
as several excellent reviews in recent years (Sada, Takano et al. 2001; Ruzza, Biondi et al. 
2009; Mocsai, Ruland et al. 2010; Riccaboni, Bianchi et al. 2010). In this chapter we aim to 
summarise current understanding of the basic structure and function for Syk, before 
developing a rationale for targeting Syk in autoimmune disease. We will then review 
progress towards Syk-directed therapies in clinical practice, and finally we shall consider 
the emerging functions of Syk beyond the adaptive immune response, and what 
implications these may have for therapy. 
2. Discovery 
Syk was identified in the early 1990s in the cytostolic fractions of lysates from porcine spleen 
and bovine thymus as a 40kDa protein with intrinsic kinase activity. This 40kDa protein was 
subsequently shown to be a fragment, containing only the catalytic domain, of a larger 
72kDa protein that was identified from a porcine spleen cDNA library (from whence it 
gained its name) using oligonucleotides designed according to the partial sequence of the 
purified 40kDa fragment (Taniguchi, Kobayashi et al. 1991). The Syk gene was subsequently 
mapped to chromosome 9q22 in humans (Ku, Malissen et al. 1994). 
3. Basic structure and function 
The Syk molecule has a multi-domain structure (Figure 1a) containing two N-terminal 
tandem Src Homology 2 (SH2) domains and a C-terminal kinase domain (Sada, Takano et al. 
2001). Interdomains A and B connect the SH2-SH2 and SH2-kinase domains, respectively. At 
least 10 major phosphorylation sites have been identified within the molecule (Furlong, 
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Mahrenholz et al. 1997) – one located in interdomain A, five within interdomain B, two 
within the kinase domain, and two near the extreme C-terminus. An alternatively spliced 
form of Syk - SykB – lacks a 23 amino acid sequence in interdomain B, and in this respect is 
similar to ZAP-70, the only other member of the Syk family of kinases. ZAP-70 has 
approximately 60% overall homology to Syk and its expression appears to be more restricted, 
in particular to T lymphocytes and natural killer (NK) cells (Au-Yeung, Deindl et al. 2009). 
In the resting state, it is thought that Syk assumes a closed, auto-inhibited structure (Figure 
1b), wherein interdomain A and interdomain B bind to the C-terminal kinase domain, 
preventing its interaction with potential substrates, in what is termed a ‘linker-kinase 
sandwich’ (Deindl, Kadlecek et al. 2007; Kulathu, Grothe et al. 2009).  Upon activation, 
structural changes within the molecule result in an open conformation that allows the 
exposed catalytic kinase domain to interact with downstream targets. 
The canonical mechanism of Syk activation is via its interaction with immunoreceptor 
tyrosine-based activation motifs (ITAMs) (Turner, Schweighoffer et al. 2000). ITAMs are 
short peptide sequences characterised by a consensus sequence that contains two tyrosine 
residues 6-12 amino acids apart. As their name suggests, they are found in association with 
the cytoplasmic components of classical immunoreceptors, including the T-cell receptor 
(TCR), B-cell receptor (BCR) and Fc-receptor (FcR) for immunoglobulins, either as an 
associated adapter protein, or within the cytoplasmic region of the receptor itself. 
 
 
Fig. 1. a. Schematic diagram showing the multi-domain structure of Syk, including two N-
terminal SH2-domains, C-terminal kinase domain, and interdomains A and B. Figure 1b: 
Schematic diagram of the ‘linker-kinase sandwich’ conformation that has been suggested for 
resting Syk (see text for details) 
Upon receptor engagement, the tyrosine residues on ITAMs are rapidly phosphorylated, 
primarily by Lyn and other members of the Src family of kinases (Figure 2). The 
phosphorylated ITAM can now act as a docking site for the SH2 domains of Syk, resulting in 
conformational changes, exposure of the kinase domain, autophosphorylation and 
propagation of downstream signalling. In addition, disruption of the ‘linker-kinase 
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sandwich’ may occur upon phosphorylation of tyrosine residues alone, particularly those 
within interdomain B. This may occur by autophosphorylation following ITAM-mediated 
activation, or by transphosphorylation by other kinases, such as Lyn or other Src family 
kinases that are often co-localised with ITAMs at the cell membrane. As a consequence, 
positive feedback and sustained Syk activity is possible in the absence of phosphorylated 
ITAMs. This ‘dual’ mechanism of activation has recently lead to the proposal of Syk as an 
‘OR’ gate in signalling pathways (Tsang, Giannetti et al. 2008; Bradshaw 2010).  
In addition to releasing the enzymatic domain of the protein from the ‘linker-kinase 
sandwich’, these changes in structure and phosphorylation, particularly within the tyrosine-
rich interdomain B, create docking sites for downstream targets of Syk, for which it can 
perform both enzymatic and adapter functions (Kulathu, Grothe et al. 2009). These 
downstream targets include a host of adapter proteins and other enzyme targets (including 
LAT, SLP76, Vav1, PLC-Ǆ, PI3K and MAP kinases) that are then able to effect complex 
cellular responses including proliferation, differentiation, phagocytosis and cytokine 
production (Mocsai, Ruland et al. 2010). 
Two groups simultaneously reported the effects of targeted disruption of the Syk gene in 
mice in the mid-90s (Cheng, Rowley et al. 1995; Turner, Mee et al. 1995). Syk knockout 
resulted in perinatal death with a severe haemorrhagic phenotype. This was subsequently 
shown to be due to a failure of communication between developing vasculature and 
lymphatics during embryogenesis (Abtahian, Guerriero et al. 2003). Analysis of Syk-
deficient lymphoid cells derived from these knock-out animals was critical in developing 
our early understanding of the functional role of Syk in immunoreceptor signalling in 
various cell types. 
Bone marrow chimera animals, reconstituted with haematopoietic stem cells from Syk-
deficient mice, showed no reduction in the numbers of circulating erythrocytes, platelets 
and total leucocytes. These animals had relatively normal reconstitution of T cells, however 
detailed analysis revealed impaired differentiation of the B cell lineage, with development 
arrested at the pro-B to pre-B cell stage, consistent with a role for Syk in pre-BCR signalling 
(Cheng, Rowley et al. 1995; Turner, Mee et al. 1995). Subsequent in vitro work, using a 
variety of cell lines and cell-based reconstitution systems, has defined a clear role for Syk in 
initiating downstream signalling following engagement of the BCR (Geahlen 2009), and 
indeed it was study in this area that was responsible for much of our understanding of the 
basic structure and function of Syk. The functional role of Syk in mature B cells (such as on 
antibody production by plasma cells) in vivo, however, is less well defined and future 
studies using small molecule inhibitors, or potentially conditional knockout in this cellular 
compartment, will be informative.  
Analysis of myeloid cells, such as macrophages and neutrophils, from Syk knockout bone 
marrow chimeras showed ablation of FcR-mediated responses including phagocytosis and 
the generation of reactive oxygen intermediates (Crowley, Costello et al. 1997; Kiefer, 
Brumell et al. 1998). The role of Syk in signal transduction for activatory FcR in these and a 
variety of other cell types is now well established, including mast cells bearing FcεR (de 
Castro 2011). A critical role for Syk in FcǄR-mediated antigen internalisation and maturation 
by dendritic cells has also been described (Sedlik, Orbach et al. 2003), and is notable given 
the important role of dendritic cells in initiating adaptive immune responses. 
In addition to FcR-mediated responses, Syk has been implicated in integrin signalling in 
myeloid cells (Mocsai, Zhou et al. 2002; Mocsai, Abram et al. 2006). Integrins are 
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transmembrane receptors that have a critical role in cell adhesion and migration, via their 
interaction with adhesion molecules expressed on other cells, particularly the vascular 
endothelium. Syk deficient myeloid cells show impaired integrin-mediated responses, 
thought to be dependent on the association of integrins with ITAM-containing adapter 
proteins such as FcRǄ-chain and DAP12, as myeloid cells deficient in these adapter proteins 
show similar defects. 
 
 
Fig. 2. Simplified schematic showing activation of Syk by interaction with ITAM.  
2a: Unengaged receptor bearing non-phosphorylated ITAM motif within its cytoplasmic tail. 
2b: Upon receptor engagement Src family kinases (SRC) phosphorylate (P) tyrosine residues 
within the ITAM motif. 2c: Phosphorylated ITAM motif acts as a docking site for the SH2 
domains of Syk, resulting in conformational changes, auto- and transphosphorylation of 
tyrosines within Syk, thus resulting in activation and phosphorylation of downstream 
targets 
4. Syk in autoimmunity 
Given our understanding of its role in BCR- and FcR-mediated signalling, the rationale for 
targeting Syk in autoimmunity is clear. The presence of autoantibodies is the hallmark of 
many autoimmune diseases. Whilst not universally pathogenic, these antibodies often 
contribute to disease via their interaction with FcR expressed on many immune effector cells 
(and other mechanisms including complement activation). Notably, FcR-deficient mice are 
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resistant to a variety of animal models of autoimmunity, and FcR polymorphisms have been 
shown to be important determinants of human autoimmune disease (Takai 2002; 
Nimmerjahn 2006). Syk inhibition may, therefore, have the desirable double effect of 
preventing the production of pathogenic autoantibodies, via inhibiting B cell activation via 
the BCR, and simultaneously inhibiting their downstream effects via disrupting signalling 
from their receptors. 
It is encouraging that other therapeutic approaches that target B-cells have recently shown 
efficacy in clinical practice (Townsend, Monroe et al. 2010). Interestingly, however, clinical 
benefit cannot always be attributed to eradication of circulating autoantibody, and it is 
probable that effects on other B cell functions, such as antigen presentation, cytokine 
production, and provision of co-stimulation to other immune cells, contribute to the benefit 
seen. Disruption of Syk-dependent BCR signalling may provide similar benefits. 
In addition, Syk inhibition may have the additional effect of inhibiting migration and 
recruitment of immune effector cells to sites of tissue inflammation, via inhibited integrin 
signalling. 
Therapeutic strategies to target Syk, therefore, are desirable and can be broadly classified 
into two main approaches: pharmacological inhibition of Syk activity, and gene-based 
therapies aiming to silence Syk expression (Ruzza, Biondi et al. 2009). Whilst the application 
of the latter has yet to advance to clinical studies, we shall briefly review their future 
potential, before focusing on the progress of Syk inhibition therapies. 
5. Gene-based therapies targeting Syk 
5.1 Antisense oligonucleotides (ASO) 
ASO are short, single stranded nucleic acid sequences that bind sense mRNA via 
complementary base-pairing, and thus inhibit the translation of the relevant protein. ASO 
directed against Syk have shown activity in a variety of cell types in vitro, including 
inhibitory effects of FcǄR-mediated signalling in monocytes (Matsuda, Park et al. 1996). 
Published in vivo studies using Syk ASO are limited to animal models of allergic 
inflammation (Stenton, Kim et al. 2000; Stenton, Ulanova et al. 2002). These have shown that 
aerosolized Syk ASO, delivered in a liposomal complex, suppress Syk expression in, and 
inflammatory mediator release from, alveolar macrophages. In addition, markers of 
pulmonary inflammation were reduced in two distinct animal models. Whilst there have 
been no in vivo studies in autoimmune models, the proposed mechanism of action in these 
allergic models is via inhibition of activatory FcR-mediated responses, suggesting similar 
approaches my be effective in autoimmune disease. However, progress in the clinical use of 
ASO based therapy has been frustratingly slow since the introduction of Fomivirsen, the 
first antisense therapy to be licensed by the Food and Drug Administration (FDA), being 
approved for use in AIDS-related cytomegalovirus (CMV) retinitis over 10 years ago. This is 
due, in part, to the difficulty of producing reliable delivery systems to target the cells, tissues 
or organs of choice (White, Anastasopoulos et al. 2009) – a not insignificant problem given 
the multi-system nature of many autoimmune diseases.  
5.2 RNA interference (RNAi) 
RNAi is an innate cellular process that is thought to regulate endogenous gene expression 
and protect against viral infection. A variety of small RNA molecules, such as endogenous, 
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genetically encoded microRNA (miRNA) or exogenous small interfering RNA (siRNA), may 
bind target mRNA via Watson-Crick complementary base pairing, and then direct this 
target mRNA into an RNA-induced silencing complex (RISC), a natural degradation 
pathway, thus effecting gene silencing prior to translation. Since this first description of 
RNAi in 1998, advance in the field has been rapid, and there have been promising early 
phase clinical studies in a number of conditions, including retinal diseases, malignancies 
and viral infections. The most commonly used technique to harness RNAi for therapy has 
been to transfect siRNA into target cells. siRNA specific to Syk, for example, have been 
shown to inhibit antibody-mediated phagocytosis by human macrophages (Lu, Wang et al. 
2011). Again, in vivo studies in this field are limited to models of allergic inflammation, and 
to date are only reported in international patent applications. Aerosolised delivery of Syk 
siRNA, using similar methods as used for ASO delivery, resulted in decreased pulmonary 
inflammation, as determined by recruitment of cells to bronchoalveolar lavage fluid, in a rat 
model of ovalbumin-induced asthma. Again, these findings augur well for the translation 
and use of RNAi in autoimmune disease. As with antisense therapy, outstanding challenges 
for harnessing RNAi include the development of effective delivery systems, escape of the 
innate ‘interferon’ response directed against foreign nucleic acids, and avoidance of ‘off-
target’ gene silencing (Davidson and McCray 2011). 
6. Pharmacological inhibition  
A number of biotechnology and pharmaceutical companies are working to develop 
compounds to inhibit Syk (Ruzza, Biondi et al. 2009; Riccaboni, Bianchi et al. 2010). To date, 
two such inhibitors, both identified by Rigel Pharmaceuticals, and now in development by 
AstraZeneca, have progressed to clinical trials – initially R112, and more recently the related 
compound, R406 (and its respective prodrug, R788). 
6.1 Preclinical studies with small molecule inhibitors 
Cell based high-throughput screening of small molecules identified R112 as a potent 
inhibitor of Syk activity, as assayed by production and release of inflammatory mediators 
following FcRε crosslinking by anti-IgE (Rossi, Herlaar et al. 2006). Subsequent 
characterization showed that R112 is an ATP-competitive inhibitor of Syk activity, as 
demonstrated by in vitro kinase assays (IC50 = 226 nmol/l). These assays also showed 
activity against other kinases such as Lyn (IC50 = 300nmol/l) and Lck (IC50 =645 nmol/l). 
However, when tested in cell-based assays, R112 was shown to be relatively selective for 
Syk as determined by phosphorylation of target proteins, despite the similar IC50 values in 
the in vitro assays.   
Rigel subsequently developed the related compound R406, another potent competitive ATP 
inhibitor for Syk (in vitro IC50 = 41 nmol/l) (Braselmann, Taylor et al. 2006). Again, 
selectivity assessments using over 90 in vitro kinase assays showed an inhibitory effect on 
other kinases, although cell based assays confirmed selectivity for Syk – FLT3 was the next 
most potently inhibited kinase, though at 5-fold less activity. R406 has been shown to inhibit 
FcR-mediated responses in a variety of cell types in vitro, including mast cells, macrophages, 
neutrophils and dendritic cells (Braselmann, Taylor et al. 2006; Matsubara, Koya et al. 2006). 
In addition, activity against BCR-mediated responses has been shown in primary human B 
cells in vitro. Notably, R406 did not show significant activity in Syk-independent pathways 
(such as following lipopolysaccharide stimulation) at the concentrations necessary to inhibit 
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FcR- and BCR-mediated pathways, in keeping with the selectivity for Syk seen in the cell 
based phosphorylation assays. R788, or fostamatinib disodium (see McAdoo and Tam 2011 
for review) was then developed as the methylene phosphate prodrug of R406, to improve its 
solubility and potential for oral dosing. 
The efficacy of R406/R788 has been studied in numerous animal models of autoimmunity. 
In a murine model of immune cytopenias, for example, treatment with R788 prevented 
haemolysis and the development of thrombocytopenia following the administration of anti-
red blood cell and anti-platelet antibodies respectively (Podolanczuk, Lazarus et al. 2009). 
Treatment with R406/R788 reduced clinical, histological and radiographic evidence of joint 
inflammation following the induction of collagen-induced arthritis, a rodent model of 
rheumatoid arthritis (Pine, Chang et al. 2007). R788 has shown efficacy in three animal 
models of SLE (Bahjat, Pine et al. 2008; Deng, Liu et al. 2010). Treatment of the lupus-prone 
NZB/NZW mouse strain reduced kidney disease, as determined by proteinuria and renal 
histology, and improved platelet counts and survival. In the BAK/BAX knockout mouse, 
treatment with R788 reduced lupus-like skin disease and lymphadenopathy. Similarly, in 
the MRL/lpr strain, treatment improved renal and skin disease, in addition to reducing 
lymphadenopathy. In a rodent model of antibody-mediated glomerulonephritis, treatment 
with R788 prevented the induction of disease (Smith, McDaid et al. 2010). In addition, 
treatment had a profound effect on established disease, reversing the histological features 
of crescentic glomerulonephritis even when initiated after the induction of disease. 
Finally, in an autoimmune diabetes model, R788 delayed the onset of insulinitis and 
spontaneous diabetes in NOD mice (Colonna, Catalano et al. 2010). Again, significant 
effects were seen even when treatment was initiated after the onset of glucose intolerance. 
Though not strictly a model of autoimmunity, treatment with R788 reduced local and 
remote inflammation in mesenteric ischaemia-reperfusion in mice (Pamuk, Lapchak et al. 
2010), suggesting effects independent of the FcR and BCR, such as inhibition of leucocyte 
migration. 
The safety of R788/R406 has also been assessed in detailed rodent toxicity and 
immunotoxicology studies (Zhu, Herlaar et al. 2007). At high doses, R406 was associated 
with a reduction in circulating lymphocyte count, bone marrow cellularity, and thymic and 
spleen weight. These changes generally resolved during a drug-withdrawal recovery 
period. In murine host resistance models, treatment with R788 did not significantly impair 
clearance of influenza, Listeria or streptococcal infection. 
Other pharmaceutical companies have developed a number of other small molecule 
inhibitors. The majority of these, like R112 and R406, are competitive inhibitors for the ATP 
binding site of the catalytic domain. Bayer, for example, has developed the 
imidazopyrimidine analogue BAY 61-3606, which inhibits Syk-mediated responses in vitro 
and has demonstrated efficacy in animal models of allergy in vivo (Yamamoto, Takeshita et al. 
2003). However, the published selectivity profile is limited to only 6 other kinases, and 
comparison with genetic knockdown suggests that BAY 61-3606 may have significant off-
target effects (Lin, Huang et al. 2010). 
Other groups have chosen to target the non-kinase domains of the Syk molecule. By 
inhibiting the interaction of the SH2-domains with their docking proteins, it has been 
proposed that Syk inhibition may be achieved whilst avoiding off-target effects on other 
kinases, and one such approach has been shown to inhibit IgE-mediated responses in vitro 
and in vivo (Mazuc, Villoutreix et al. 2008). Whilst the precise molecular mechanism of the 
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inhibitory effects of this molecule are yet to be definitively described, it should be noted 
that the SH2-domain is a highly conserved motif found in a large number of proteins 
involved in signal transduction, and targeting this domain may in turn have diverse off 
target effects.  
6.2 Clinical studies  
R112 was the first Syk inhibitor treatment to be assessed in clinical studies, where it showed 
benefit in relieving symptoms of allergic rhinitis when delivered as an intranasal 
preparation (Meltzer, Berkowitz et al. 2005). Subsequent work focused on R406/R788, with 
early phase clinical studies confirming that R406/788 is highly bioavailable following oral 
administration, rapidly absorbed systemically, and well tolerated at doses needed to achieve 
biological effects such as inhibition of basophil activation in response to anti-IgE ex vivo (IC50 
1.06 microM) (Braselmann, Taylor et al. 2006; Sweeny, Li et al. 2010).  
To date, the results of five phase II studies with R788 (fostamatinib) have been published. 
Three of these investigated the effects of fostamatinib in rheumatoid arthritis (RA) (Table 1). 
The first recruited almost 200 patients with active disease despite standard therapy with 
methotrexate (Weinblatt, Kavanaugh et al. 2008). Clinical responses were seen as early as 
one week following the initiation of treatment, and sustained at three months, with 
significant improvements in disease activity scores in the treatment groups versus placebo. 
The second study enrolled over 450 patients with active disease despite long-term 
methotrexate therapy, and this confirmed benefit at six months, with improved American 
College of Rheumatology 20% improvement criteria (ACR20), ACR50, ACR70 and DAS28 
scores (Weinblatt, Kavanaugh et al. 2010). Notably, both these studies included a significant 
proportion of patients who had failed biological therapy with anti-TNF or anti-CD20 agents, 
and benefit with fostamatinib was seen in these subgroups (although overall response rates 
were lower than for the whole study population). A subsequent trial designed specifically to 
examine the efficacy of fostamatinib in this group of patients failing biologic therapy, 
however, did not achieve its primary endpoint of improved ACR20 in the treatment group 
(Genovese, Kavanaugh et al. 2011). There were, however, significant improvements in 
radiographic and biochemical markers of inflammation. 
A small open label study in immune thrombocytopenic purpura (ITP) has also shown 
promising results (Podolanczuk, Lazarus et al. 2009). Although the numbers are small 
(n=16), the majority of patients had refractory disease with multiple previous ITP treatments 
(commonly steroids, intravenous immunoglobulin, rituximab and splenectomy). As such, 
the sustained (50%) and transient (25%) response rates seen during the average follow up 
time of 36 weeks represent encouraging results and further studies are planned. 
In addition to these studies in autoimmune disease, a fifth phase II study examined the 
effects of fostamatinib in haematological malignancy (Friedberg, Sharman et al. 2010), the 
rationale for which is discussed below. Again, in a study population that included a 
significant proportion of patients with heavily pre-treated, relapsed or refractory disease, 
fostamatinib showed modest but significant clinical activity and a manageable side-effect 
profile. 
The most frequent adverse event seen in these clinical studies was gastrointestinal toxicity, a 
common side effect of many kinase inhibitors. Symptoms were dose-related, and seen at 
rates of up to 45% in groups receiving the highest doses of fostamatinib, and this was the 
most common reason for patient withdrawal from the RA trials. 
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Neutropenia occurred in up to 30% of patients receiving fostamatinib in the RA trials. 
Again, this finding appeared to be dose-related and responded to dose reduction or 
temporary withdrawal of the drug. Although no direct pharmacokinetic interaction has 
been detected between fostamatinib and methotrexate (Baluom, Samara et al. 2011), 
synergistic effects on haematopoiesis beyond individual pharmacokinetic parameters (along 
with underlying bone marrow disease or other concomitant immunosuppressant therapy) 
may have contributed to this phenomenon, as neutropenia was not reported in the ITP trial. 
An increased rate of uncomplicated upper respiratory tract infections was seen in the 
treatment group of the largest RA trial. However, this was not associated with neutropenia. 
In addition, no opportunistic or atypical infections were reported in any of the clinical trials. 
7. Beyond adaptive immunity: problems and potential for Syk-directed 
therapy 
Recently, Syk has been implicated in a number of signalling pathways beyond the adaptive 
immune response that may have implications for Syk-directed therapy in clinical practice. 
These include the aforementioned role in cell adhesion, as well as possible roles in innate 
immunity, platelet function, bone metabolism and tumorigenesis (Mocsai, Ruland et al. 
2010). Disruption of these functions may lead to significant toxicity, or alternatively open 
novel therapeutic avenues, in targeting Syk. The basic mechanism of these functions has 
been reviewed in detail elsewhere (Mocsai, Ruland et al. 2010); we shall here consider the 
potential clinical implications. 
7.1 Innate Immunity and Infection 
Given its diverse effects on adaptive immune responses, coupled to a role in inflammatory 
cell adhesion and migration, the preeminent concern with Syk directed therapies must be of 
over-immunosuppression and the associated risk of infection. It is also notable that Syk has 
recently been associated with a variety of pathogen recognition receptors (PRRs), important 
components of the innate immune response that recognise pathogen-associated molecular 
patterns (PAMPs). C-type Lectins, one such class of PRR, play an important role in 
antifungal immunity in particular, and Syk has been implicated in the intracellular 
signalling cascades for these receptors (Drummond, Saijo et al. 2011). Some, such as Dectin-
1, contain an ITAM motif on their cytoplasmic domain, and others may associate with ITAM 
containing adaptor proteins such as FcRǄ chain or DAP12. As such, Syk inhibition may 
potentially lead to excessive downregulation of multiple inflammatory, innate and adaptive 
immune responses, resulting in risk of overwhelming infection. The results of the preclinical 
toxicity assessments and host resistance models are reassuring in this respect (although a 
host resistance model of fungal infection has not been studied), as is the absence of severe, 
atypical or opportunistic infection in the clinical studies thus far. Larger and longer clinical 
studies are, however, needed to establish the long term and cumulative effects of Syk 
inhibition on innate immune responses and infection risk, particularly in patient groups 
who have had extensive treatment histories with other immunosuppressant agents. 
7.2 Platelet function 
Syk has been shown to be involved in a number of platelet activation pathways, including 
via the glycoprotein GPVI receptor (an FcRǄ chain-associated receptor that bears an ITAM 
motif), integrin ǂIIbǃ3, and C-type Lectin 2 (CLEC-2; a type II membrane protein containing 
www.intechopen.com
 
Spleen Tyrosine Kinase: A Novel Target in Autoimmunity 
 
51 
a single tyrosine-based motif in its cytoplasmic tail that has been termed a hemITAM) 
(Watson, Auger et al. 2005; Watson, Herbert et al. 2010). In addition, R406 has demonstrated 
inhibitory activity in these pathways (Spalton, Mori et al. 2009). Notably, however, very 
high dose exposure to R406 did not prolong bleeding time in mice, and in phase I human 
studies, R406 did not inhibit collagen or ADP-induced platelet aggregation ex vivo 
(Braselmann, Taylor et al. 2006), perhaps suggesting redundancy of Syk dependent pathways in 
vivo. Based on these observations, it would appear that targeting Syk in isolation would not be 
an effective anti-thrombotic therapy. However, synergistic effects, potentially both therapeutic 
and harmful, with other anti-platelet agents have not been explored in clinical studies. 
7.3 Bone metabolism 
Syk has been shown to regulate osteoclastic bone resorption, via its association with integrin 
ǂvǃ3 and ITAM bearing proteins, such as DAP12 and FcRǄ chain, expressed at the 
osteoclast cell surface (Zou, Kitaura et al. 2007). In addition, Syk has recently been 
implicated in the suppression of osteoblast differentiation (Yoshida, Higuchi et al. 2011). 
Thus, Syk may represent a therapeutic target in disorders of bone metabolism such as 
osteoporosis, although potential effects of Syk inhibition on normal bone, such as 
osteosclerosis and increased fragility and fracture risk, have yet to be investigated in vivo or 
in clinical studies. 
7.4 Tumorigenesis 
It has been suggested that Syk is a negative regulator of progression in various types of 
malignancy (including breast, gastric and melanoma) based on the observation of decreased 
Syk expression in these tumour types and experimental studies where Syk transfection and 
re-expression in tumour cell lines suggested a tumour- and metastasis- suppressive effect 
(Coopman and Mueller 2006). The molecular mechanism of this suppressive role has yet to 
be established. Conversely, fostamatinib has shown activity in NCI-60 (a panel of 60 diverse 
human cancer cell lines), although this may be due to off-target effects, rather than Syk 
inhibition specifically.  On this basis, however, a broad multi-histology Phase II study is 
currently recruiting (NCT00923481). 
Syk signalling through the BCR has also been implicated as an important survival signal in 
various lymphoid malignancies, and R406 has shown antiproliferative and proapoptotic 
activity in B cell lymphoma and CLL lines in vitro (Chen, Monti et al. 2008; Buchner, Fuchs et 
al. 2009; Quiroga, Balakrishnan et al. 2009). Furthermore, R788 is highly active in animal 
models of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) 
(Young, Hardy et al. 2009; Suljagic, Longo et al. 2010), and in a Phase II clinical trial, 
fostamatinib showed significant clinical activity in a heterogeneous group of NHL and CLL 
(Friedberg, Sharman et al. 2010). Based on these findings, larger Phase II trials in 
haematological malignancy are ongoing (NCT00446095, NCT00798096). Interestingly, some 
oncogenic viruses have been shown to encode ITAM-containing proteins – for example, 
Epstein Barr virus (EBV) latent membrane protein 2A (LMP2A) contains an ITAM motif, and 
has been shown to promote B cell development and survival (Caldwell, Wilson et al. 1998). 
7.5 Cardiovascular risk 
Hypertension was a commonly reported adverse event in clinical studies with fostamatinib. 
It is unclear whether this was due to Syk inhibition per se, or potentially due to off-target 
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effects on other kinases – the vascular endothelial growth factor receptor 2 being a putative 
candidate. Whilst usually mild, and responsive to dose reduction of fostamatinib or 
augmented antihypertensive therapy, the long-term effects of even small increases in blood 
pressure in patients with autoimmune rheumatic diseases such as RA and lupus, who 
already have dramatically increased cardiovascular risk, need to be considered. 
Interestingly, administration of fostamatinib was recently shown to attenuate plaque 
development in a rodent model of atherosclerosis, an effect thought to be mediated by 
impaired recruitment of inflammatory cells, suggesting that Syk inhibition is a potential 
target in atherosclerotic cardiovascular disease (Hilgendorf, Eisele et al. 2011). Syk has also 
been implicated in the mechanism of high-glucose induced NF-κB activation in glomerular 
endothelial cells, suggesting a potential role of Syk inhibition in preventing end-organ 
complications of diabetes mellitus (Yang, Seo et al. 2008). 
8. Conclusions 
The rationale, the experimental data, and the clinical experience to date augur well for the 
efficacy of Syk inhibition in autoimmune disease. Several large phase II-III trials in RA are 
currently in progress (NCT01242514, NCT01264770, NCT01197521, NCT01197534, 
NCT01197755) and it is hoped that if successful, efficacy could translate to a wide range of 
organ-specific and systemic autoimmune diseases. Indeed, it is tempting to propose that 
Syk-directed therapy, with its proven clinical efficacy in early trials, along with potential 
benefits in cardiovascular disease, hyperglycaemia, bone metabolism and malignancy 
(particularly those related to oncogenic viruses) is the proverbial ‘Holy Grail’ of 
immunosuppressant therapy following 40 years of steroid- and cytotoxic-based regimes 
complicated by hypertension, diabetes, osteoporosis and lymphoproliferative disease. 
However, the widespread role of Syk in numerous immune functions raises serious 
concerns regarding the risk of opportunistic infection, and some questions about the 
oncogenic potential of Syk disruption in certain cell types remain unanswered. In addition, 
it is disappointing that Syk inhibition with fostamatinib, the drug furthest through clinical 
development, showed only improvement by objective assessment using MRI or biochemical 
markers, rather than clinical benefit in patients who had not responded to biologic therapy. 
Future clinical studies will need to establish both the long-term safety and superiority of Syk 
inhibition in practice. 
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